ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

GZR102

A development code. Also written as “GZR102 injection”.

Its studies are mostly in Diabetes Mellitus, Type 2, led by Gan & Lee Pharmaceuticals.

Furthest: phase 2, since Jun 27, 20252 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gan & Lee Pharmaceuticals22 open or runningphase 2since Jun 27, 2025Apr 28, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 28, 2025First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT06974487 · 30 planned · China
  2. Jun 27, 2025Phase 2 study in Diabetes Mellitus, Type 2NCT07055386 · 90 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07055386Diabetes Mellitus, Type 2 · China2Active, not recruitingJun 28, 202690
NCT06974487Diabetes Mellitus, Type 2 · China1Not yet recruitingSep 30, 202530

How it is read

Names in the registry

  • “GZR102”, 1 entry
  • “GZR102 injection”, 1 entry

Codes read as this program: GZR102.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.